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T
racer techniques have become an established
part of metabolic research and indeed are a
fundamental part of our understanding of carbo-
hydrate metabolism in humans. This review is
meant to provide a basic overview of the problems and
potential pitfalls associated with these techniques in the
hope that they are reliably applied to newer areas of
research.
A quantitative measurement of the substrate ﬂuxes that
determine fasting or postprandial glucose concentrations
is central to the determination of the pathophysiology of
disease states and of measuring the effect of therapeutic
interventions on the disease state. During the fasting state,
glucose concentrations are dependent on the rate of
endogenous glucose production (EGP) relative to the rate
of glucose disappearance; measurement using tracer tech-
niques is quite straightforward. The situation is more
complex in the postprandial state, where gastric emptying,
glucose absorption, the net sum of splanchnic extraction
of ingested glucose (and therefore the rate of systemic
appearance of ingested glucose), EGP, and glucose disap-
pearance determine postprandial glucose concentrations
(1,2). The tracer-based methodologies used to measure
these ﬂuxes, and their potential pitfalls, will be discussed.
Tracers: stable vs. radioisotopes. The use of a sub-
stance (tracer) that can be used to follow a naturally
occurring substrate (tracee) requires that such a sub-
stance experience the identical metabolic fate as the
tracee. The ideal tracer can be detected with such preci-
sion as to require administration in trace amounts, thereby
avoiding any alteration in the metabolism of the tracee (3).
Tracers used for the purpose of metabolic research in
humans are usually identical to the tracee, except that one
or more atoms differ from the more abundant naturally
occurring form of that atom.
Such isotopes are radioactive when they spontaneously
disintegrate to form another element, releasing radiation
as a by-product of the decay. For example,
3H, which has
one proton and two neutrons, emits an electron when
decaying to
2He (two protons and one neutron). The
energy emitted by such disintegrations is detectable by a
scintillation counter. The rate of decay of such isotopes
may determine their utility or otherwise in the study of
human metabolism; in practice, isotopes with a short
half-life are typically not used in metabolic studies except
to image metabolic events in speciﬁc tissues.
Stable isotopes also differ in the number of neutrons
present but do not decay spontaneously and therefore do
not emit radiation. Gas chromatography–mass spectrome-
try is necessary to distinguish such isotopes. To be of use
in metabolic research, the natural abundance of a given
isotope (and the presence of multiple other isotopes)
needs to be low. Other than the absence of radiation
exposure associated with the use of stable isotopes, there
is another important key distinction from radioisotopes.
The presence of naturally occurring stable isotopes within
the body prior to tracer infusion means that the tracer
(merely) enriches the amount of this isotope. Knowledge
of the background abundance of the isotope is necessary
to determine the degree of enrichment required.
While scintillation counting is sufﬁciently sensitive to
detect small quantities of radioisotope, permitting infusion
of “massless” amounts of tracer, this is not the case with
mass spectrometry. The use of stable isotopes generally
requires infusion of amounts of labeled compound large
enough that the mass of tracer infused is signiﬁcant and
must be accounted for when calculating a metabolic rate
using such isotopes.
The assumption that tracers are treated in identical
fashion to their naturally occurring counterparts under-
pins all tracer methodology. However, the presence of
radioactive impurities can introduce signiﬁcant errors into
calculations (4,5). This is because a portion of the radio-
active material infused is not behaving as a tracer but as a
“bystander” playing no role in the reaction rate being
measured and with a clearance rate an order of magnitude
lower than that of glucose.
The unit of enrichment for a radioactive tracer is
speciﬁc activity (SA), where:
SA 
tracer
tracee 
dpm
mol (1)
Since the tracer is massless, the amount of tracer is
represented by disintegrations per minute (dpm). In con-
trast, due to the fact that stable isotopes are not massless
and because stable isotopes require higher enrichment to
be accurately measured, their enrichment is:
enrichment 
tracer
tracer  tracee (2)
Commonly this is expressed as atom percent excess (APE)
to account for the presence of naturally occurring stable
isotopes:
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tracer
tracer  tracee 
100
1 (3)
There is concern that the degree of enrichment necessary
with stable isotopes can induce side effects or directly
affect metabolism. To some extent, the variability in
measurement of isotopes seems to be greater than any
isotope effect (3). However, a recent study using a variant
of the deuterated water method suggested that the deute-
rium on C5 of glucose is lost more rapidly relative to the
deuterium on C3 (6).
The Steele equation. At the simplest level, glucose
metabolism in the fasting state can be reduced to a single
compartment represented by a bathtub where water en-
ters via a faucet (EGP) and leaves via the drain (glucose
disappearance [Rd]). The water level rises if EGP  Rd,
falls if Rd  EGP, and is constant when EGP  Rd, as
happens during fasting or in a clamp when peripheral
glucose concentrations are kept constant. If a dye could be
added to the water in such a way that it is instantaneously
and uniformly distributed throughout the bathtub, subse-
quent water loss via the drain will not change the resulting
dye concentration in the bathtub. In contrast, water enter-
ing from the faucet has no dye and over time will dilute the
dye concentration. This underlies the basis of the tracer
dilution technique, commonly used to measure EGP where
unlabeled glucose dilutes the tracer.
In fact, tracers used to measure metabolic ﬂuxes are
usually infused at a (constant) rate so that after a period of
time the tracer will be removed at the same rate that it
appears. The time to reach that equilibration period (as-
suming a one-compartment system with constant tracer
infusion) depends on the tracer’s infusion rate relative to
the tracer’s clearance (removal from the pool). Assuming
that the tracer and tracee are cleared at the same rate (i.e.,
isotopic discrimination does not occur), the concentration
of tracer and tracee in the body pool will reﬂect their
respective rates of infusion/appearance (7,8) (Fig. 1).
As a method for measuring EGP, the model described
could feasibly be used to measure EGP assuming that a
human behaves like a single-compartment pool, where
tracer and glucose are uniformly distributed. However, in
most experimental situations, where the steady state is
perturbed by a sudden inﬂux of glucose and the secretion
of insulin changes the rate of EGP and glucose efﬂux,
these assumptions do not hold because glucose is not
entering a uniform pool—the sampled pool does not
necessarily reﬂect the pool into which glucose initially
appears. Glucose crosses (and is extracted by) multiple
compartments before entering the circulating glucose
pool, which is the pool usually sampled.
However, let us persist for a while with the single-
compartment bathtub analogy before progressing to dif-
ferent situations. The equation that is most relevant to
simple measures of glucose ﬂux is:
Ra 
F
SA (4)
where Ra is rate of appearance and F is rate of tracer
infusion. Solving for SA:
Ra 
F
tracer 
tracee
1 (5)
Steady state vs. non–steady state and Steele volume.
In situations where the relative concentrations of tracer
and tracee are stable, Ra can be calculated accurately.
This is because the assumption that a tracer is well mixed
with the tracee holds (8) and once the tracer (and tracee)
has left the pool, it does not re-enter.
A perturbation to the steady state, e.g., a (sudden)
decrease in EGP caused by insulin injection, will decrease
dilution of the tracer by cold glucose. The consequent
rapid changes in SA decrease the accuracy with which
glucose ﬂux can be calculated (9).
To account for the sudden changes in both tracer and
tracee concentrations, the equation can be modiﬁed to
account for these changes over time (dSA/dT). However,
because glucose is not distributed in a single pool, the
prior assumptions of uniform mixing and a lack of reentry
into the pool being sampled may not hold. Therefore, it is
reasonable to postulate the presence of at least two pools:
a rapidly equilibrating pool and a slow(er)-equilibrating
pool (10,11). The complexities of a multiple-pool system
can be simpliﬁed to that of a single-compartment system
by using a pool fraction (p) of the total extracellular
glucose pool (Vtotal)  the Steele volume (VSteele), e.g., 0.65
of 200 ml/kg. In such circumstances the non–steady-state
correction at two given time points T1 and T2 is:

pV  glucose1  glucose2/2
1 
SA2  SA1
T2  T1 

1
SA1  SA2/2 (6)
The potential problem with this approach is that the size of
the pool is probably not constant and changes with time
after a given perturbation (12). The same applies to the
equilibration rate of tracer between compartments (10).
Furthermore, disease states may alter the magnitude of
differences between compartments, introducing new er-
rors into the calculation of glucose ﬂux. In such situations,
calculation of glucose ﬂuxes (see below) may produce
aberrant results, e.g., negative values for EGP. Such errors
can be minimized by using an experimental design where
perturbations in SA are minimized and frequent sampling
occurs (so that these perturbations in SA are very small
quantities) or by ﬁtting the data to minimize changes in SA
(13).
An alternative approach to the assumption of pV is to
measure this volume during the experiment. Issekutz et al.
(14) proposed a method in which a (separately) infused
Glucose
Endogenous Glucose Production
Glucose Disappearance
F
Pool a
Pool b
Vab
G
Vba
FIG. 1. Schematic diagram illustrating the multiple-pool concept in
tracer dilution studies. Pool a represents the readily accessible pool in
which tracer distributes rapidly, in contrast to the less readily acces-
sible pool (Pool b). The relative size of each pool can be altered by
experimental (or physiological) conditions, as can the ﬂow of tracer
(and tracee) from Pool a to b (Vab) and vice versa (Vba). F, tracer
infusion rate.
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isotope of glucose mixed with exogenously infused glu-
cose. Since the infusion rate and therefore the Ra of both
isotopes into the systemic circulation is known, pV can be
measured. This methodology has been compared with the
non–steady-state calculation when using a variation of the
hot-GINF technique (15) (outlined below) and yields sim-
ilar results (16,17).
Measurement of glucose turnover using a clamp. A
euglycemic-hyperinsulinemic clamp is a straightforward
experimental design that approximates the bathtub exam-
ple used above to describe glucose metabolism. The
design is amply suited to measurement of glucose turnover
using a single tracer because by design a steady state is
reached after a prolonged period of time where the Ra is
equal to the Rd and the SA is relatively constant. For
example, using 3H
3-glucose as the tracer:
SA 
3H
3 glucose (dpm/ml)
glucose (mol/ml)  dpm/mol (7)
Therefore,
Ra  Rd  F/SA  mol/min (8)
where F  rate of tracer infusion (dpm/min).
Provided the tracer is infused for an adequate amount of
time, baseline EGP can be calculated in the same fashion.
However, if glucose turnover is to be measured at multiple
time points with multiple perturbations, e.g., to establish a
dose-response curve for insulin, it is best to design an
experiment that avoids large changes in the SA, thereby
minimizing the need to make assumptions regarding the
structure or degree of mixing of accessible and remote
glucose pools (13,18).
Changes in SA can be minimized by infusing glucose
that contains tracer in amounts that approximate the
baseline plasma glucose SA (16,19). A primed, continuous
infusion of tracer is initiated and continued till the end of
the study. Provided a suitable equilibration period elapses,
such an infusion can readily be used to measure fasting
EGP as described above. Subsequent to the infusion of
insulin and intravenous glucose, the rate of infusion of this
tracer is decreased to approximate the anticipated fall in
EGP, thereby keeping the ratio of tracer to tracee constant
(13,19).
Anticipation of the expected fall in EGP requires a priori
knowledge of the degree and pattern of change in this
parameter. In one of the examples cited (19), the basal
infusion of [3-
3H]glucose was altered so as to approximate
the anticipated pattern of fall of EGP (0 to 10 min, 90%; 10
to 20 min, 80%; 20 to 30 min, 65%; 30 to 40 min, 55%; 40 to
50 min, 45%; 50 to 75 min, 35%; 75 to 120 min, 40%; 120 to
300 min, 45%; 300 to 360 min, 50%). The necessary infor-
mation to generate such general patterns can be obtained
from other experiments or pilot studies. Error is reduced
by more frequent sampling during the 60–90 min subse-
quent to such a perturbation. The success or otherwise of
such a technique can be measured in the degree of
perturbation observed in SA and the basal infusion rates
adjusted prior to conducting the experiment(s).
The infusion of intravenous glucose delivers “hot” and
“cold” glucose-minimizing perturbations in SA. In such
circumstances:
F  dpm/min  infusion rate1  SAinfusate2
 infusion rate2 (9)
Therefore, since
Ra  F/SA  mol/min (8)
EGP  Ra  glucose infusion rate (10)
Rd  EGP  glucose infusion rate ( Ra in a clamp)
(11)
Assuming SA can be kept relatively constant over time,
thereby minimizing the non–steady-state correction, such
a technique can be effectively used in experiments mim-
icking the systemic appearance of orally ingested glucose
(Fig. 2).
An issue that arises when reporting ﬂux is that of data
normalization so as to allow interindividual comparison of
results. The approach most often adopted is to express
turnover per unit of lean body mass or unit of surface area.
This needs to be borne in mind when comparing results
between different investigators.
So far we have considered perturbations to SA that arise
from meal ingestion. However, it is important to appreci-
ate that sudden increases in physical activity can perturb
SA by causing an increase in glucose disappearance.
Assuming that the tracer infusion rate does not change in
anticipation, SA will fall leading to an overestimation in
the ﬂux being measured.
Measurement of splanchnic glucose uptake: dual-
tracer methodology. The dual-isotope method was de-
veloped in an effort to simultaneously measure both the
systemic Ra of ingested glucose (Rameal) and postprandial
EGP (20). This method uses an infused and an ingested
tracer to trace glucose. The appearance of ingested glu-
cose is calculated by multiplying the Ra of the ingested
tracer by the tracer-to-tracee ratio of the ingested meal.
Initial splanchnic glucose uptake can be calculated by
subtracting the portion of the ingested glucose that
reaches the circulation from the total amount of glucose
ingested. Endogenous glucose production is calculated by
subtracting Rameal from the total glucose appearance.
This experimental approach has been used by a large
number of investigators to study postprandial glucose
metabolism in a wide variety of species. However, results
have not always been consistent. Estimates of initial
splanchnic glucose uptake by this method have varied
widely, as has the pattern of EGP, ranging from rapid
near-complete suppression to an initial paradoxical rise
followed by a subsequent fall in EGP (21). These discrep-
ancies are likely to arise from inadequacies of the model
used to calculate turnover in the rapidly changing condi-
tions occurring after carbohydrate ingestion. As previ-
ously reviewed, estimates of initial splanchnic glucose
with this technique vary between 	0 and 30% (21).
A partial solution to these problems is to use an in-
traduodenal infusion of labeled glucose whose Ra can be
determined by a systemic tracer (22–24) (Fig. 3). In such
experiments, 3H
3-glucose was infused intraduodenally
while [6,6-
2H2]-glucose was used as the systemic tracer.
Once steady state is achieved, Ra and Rd is calculated
using a derivation of the Steele steady-state equation:
Rd  Ra 
FD2glucose
MPE6,6-
2H2glucose  FD2glucose (12)
where F[D2glucose] is the [6,6-
2H2] tracer infusion rate and
MPE [6,6-
2H2]glucose is the plasma [6,6-
2H2]glucose en-
richment. Note that the calculation must account for
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have been the case for a radioisotope. The systemic Ra
of the intraduodenally infused 3H
3-glucose can be cal-
culated as:
Ra 3H
3-glucose 
FD2glucose
6,6-
2H2glucose/3H
3glucose (13)
where [6,6-
2H2]glucose is the concentration (in mol/ml)
of [6,6-
2H2]glucose in plasma and [3-
3H]glucose is the
concentration (in dpm/ml) of [3-
3H]glucose in the plasma.
The systemic Ra of the intraduodenally infused glucose
can subsequently be calculated as:
Raduod glucose  Ra 3H
3-glucose  SAduod glucose
(14)
where SAduod glucose is SA (in dpm/mol) of the glucose
infused intraduodenally. Initial splanchnic glucose uptake
(SGU) can subsequently be calculated:
SGU  Gduod  Raduod glucose (15)
where Gduod is the intraduodenal infusion rate of glucose.
EGP is calculated by subtracting the sum of the intrave-
nous glucose infusion rate (F[D2glucose]) and the systemic
Ra of intraduodenally infused glucose from total glucose
appearance.
While this methodology is relatively simple, it has three
problems: It cannot distinguish between the intestinal and
hepatic contribution(s) to SGU. Furthermore, it requires
the cumbersome and invasive placement of a nasoduode-
nal feeding tube, and it does not replicate postprandial
conditions.
Glucose turnover in meal studies: triple-tracer meth-
odology. The inadequacies of the dual-tracer method for
meal studies arise in part because a one-compartment
model cannot describe the non–steady-state conditions
that occur after meal ingestion. In addition, a ﬁxed pool
fraction cannot account for incomplete mixing within the
compartment, and indeed the “correct” value is uncertain
and may vary with time (16,21,25,26). The presence of
concentration gradients within the glucose pool results in
errors that may depend on disease state (diabetic vs.
nondiabetic) and methodology (meal size, rapidity of
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FIG. 2. An experiment using intravenous infusion of glucose to mimic the systemic appearance of oral glucose (A). The tracer [3-
3H]glucose is
infused via two separate infusions (B), so that tracer infusion 1 mimics the expected decline in EGP. Tracer infusion 2 reﬂects the glucose
infusion replicating systemic appearance of oral glucose. Despite large, rapid changes in glucose concentration, the SA is relatively constant over
time (C), enabling accurate measurement of EGP (D).
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Systemic appearance of intraduodenally infused 
glucose = Ra of intraduodenal glucose
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Liver & 
Splanchnic
Tissues
FIG. 3. Methodology for the determination of splanchnic glucose
uptake (SGU) using a nasojejunal tube.
A. VELLA AND R.A. RIZZA
diabetes.diabetesjournals.org DIABETES, VOL. 58, OCTOBER 2009 2171ingestion/appearance, etc.). Such errors are not necessar-
ily overcome with multiple-compartment models (27,28).
Methodology that can ensure a relatively constant tracer-
to-tracee ratio overcomes these problems when measuring
glucose turnover using a clamp (see above). Therefore, in
an effort to overcome the marked changes in glucose and
tracer concentrations that occur after meal ingestion using
a dual-tracer approach, the addition of a third tracer was
conceived as a reﬁnement of the dual-tracer method. For
example, with this design the meal glucose is labeled with
a tracer (e.g., [1-
13C]-glucose), while a second tracer (e.g.,
[6,
3H2]-glucose) is infused intravenously in a manner an-
ticipated to mimic the systemic appearance of meal-
derived glucose.
In this way, the ratio of [6-
3H] glucose to [1-
13C]
glucose and of [6,6-
2H2]glucose to endogenous glucose
(the portion of glucose derived from EGP) remain rela-
tively unchanged. As before, changes in the ratio between
[6,6-
2H2]glucose tracer and endogenous glucose are mini-
mized by infusing [6,6-
2H2]glucose in a pattern that mimics
the anticipated pattern of change of EGP. This approach is
virtually model independent, yielding essentially the same
results when interpreted using steady-state or non–steady-
state assumptions and either a one- or two-compartment
model. When compared with a dual-tracer approach, min-
imizing change in the plasma tracer-to-tracee ratios, accu-
rate measurement of the factors involved in the regulation
of postprandial glucose tolerance is possible (27).
In this experimental design, [6-
3H] glucose is used
to trace the systemic appearance of [1-
13C] glucose.
Therefore:
Ra13c 
F3H
glucose3H/glucose13C
(16)
Consequently,
meal Ra  Ra13c 
1
meal enrichment (17)
where
1
meal enrichment is the ratio of total glucose
(tracer 
 tracee) to tracer in the meal. To calculate EGP,
consider that total plasma glucose concentration is the
sum of tracee plus two tracers ([6-
3H]glucose being
massless):
total glucose  Gnatural  G13C  G2H (18)
Since G13C and G2H can be quantiﬁed, the equation can be
solved for Gnatural. Subsequently, the concentration of
glucose derived from EGP can be calculated by subtract-
ing the contribution of ingested natural glucose from
Gnatural.
Gendogenous  Gnatural 
G13C
ttrmeal
(19)
where ttrmeal is the ratio of tracer to tracee in the meal.
EGP is then calculated as:
EGP 
F2H
G2H/Gendogenous
(20)
where F2H is the infusion rate of [6,6-
2H2]-glucose. Finally:
Rd  (meal Ra  EGP  F2H)
 correction for glucose/t in the pool (21)
Therefore:
Rd  meal Ra  EGP  F2H  pV
dG
dt (22)
where pV is VSteele as discussed above and G is glucose
concentration. This ﬁnal calculation depends on multiple
assumptions known to be incorrect (see discussion
above). However, calculation of Rd using the triple-tracer
approach is little affected by different estimates of pool
size or a single- versus dual-compartment approach, un-
derlining the model independence of this methodology
(Fig. 4).
Tracer choice and its effects on measurement of
glucose ﬂux. An important assumption underling tracer
methodology is that the label used in a given tracer does
not recycle into the compartment being studied after it
leaves the compartment with the tracee. If this is the case,
Ra will be progressively underestimated as more and more
isotope recycles back into the pool being measured.
Glucose tracers typically use a hydrogen isotope on the
2nd, 3rd, or 6th carbon. The label is lost to water at
different points during glycolysis or gluconeogenesis, lead-
ing to potential differences in Ra measurement depending
on the tracer used (3,29).
In the case of glucose labeled on the 2nd carbon, the
isotope will be lost in the conversion of glucose-6-phos-
phate to fructose-6-phosphate (assuming that the isomer-
ase reaction is much more active compared with the
formation of glucose-6-phosphate) and reconversion to
glucose-6-phosphate. This results in overestimation of
glucose utilization (4,30). Since the glucose/glucose-6-
phosphate cycle results in hydrolysis of ATP but without
glucose metabolism, this has been termed futile cycling
(31).
On the other hand, label is lost from the 3rd carbon after
cleavage of fructose-6-phosphate to dihydroxyacetone
phosphate (DHAP) and glyceraldehyde-3-phosphate (G-
3P). The label is present on the 1st carbon of DHAP but is
then lost after isomerization to G-3P.
In the case of glucose labeled on the 6th carbon, label
is lost from the 6th carbon after entry into the tricar-
boxylic acid cycle. The action of uridine-diphosphoglu-
cose dehydrogenase causes loss of tritium from carbon
6 when uracil-diphosphate (UDP)-glucose reenters glu-
cose metabolism (32). Another potential mechanism by
which the label on the 6th carbon is lost is when glucose
is metabolized to fructose biphosphate and then recy-
cles back to glucose. A variety of (in vitro) studies have
demonstrated that futile cycling can occur at the fruc-
tose-6-phosphate/fructose diphosphate level (33–35).
However, in vivo studies suggest that in postabsorptive
humans, futile cycling at this level is insigniﬁcant
(36,37). The use of 6,6-
2H2-glucose as a tracer over-
comes some of these problems, as the 6-
2H1-glucose
product of recycling can be distinguished from the
underlying tracer (38).
There is no net loss of carbon in glycolysis, and there-
fore the use of a carbon-labeled tracer in measuring
glucose metabolism avoids some of the potential pitfalls
associated with the use of hydrogen labeling. Generally,
1-
13C-glucose, 6-
13C-glucose, or universally labeled glucose
(U-
13C-glucose) is used. Use of the latter tracer decreases
potential problems associated with the other tracers of
recycling label that underestimate glucose production
(39). This assumes that the likelihood of two triply labeled
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13C-glucose
during gluconeogenesis is extremely small. Such potential
pitfalls and the likely presence of such cycling during the
study conditions need to be considered when choosing a
tracer for a given study (40,41).
Conclusions. The evolution of tracer techniques enabled
an understanding of basic physiologic processes in free-
living organisms. Established techniques such as those
outlined above are routinely used to measure carbohy-
drate metabolism and subsequent changes in response to a
given intervention. Newer methodologies, while more es-
oteric and perhaps less widely applicable, nevertheless
depend on the same principles outlined in this review.
Ultimately, the aphorism that to detect a change one has to
be able to measure it applies to metabolism too—we hope
that properly applied tracer methodology will continue to
drive innovative metabolic research in the near and distant
future.
ACKNOWLEDGMENTS
Support was received from the Mayo Clinic General Clin-
ical Research Center. A.V. is supported by National Insti-
tutes of Health (NIH) Grant DK078646, and R.A.R. is
supported by NIH Grant DK29953.
The experiments described were performed in the Mayo
Clinic Research Unit, which is supported by grant 1 UL1
RR024150-01 from the National Center for Research Re-
sources (NCRR), a component of NIH and the NIH Road-
map for Medical Research. The contents of this article are
solely the responsibility of the authors and do not neces-
sarily represent the ofﬁcial view of NCRR or NIH. Infor-
mation on NCRR is available at http://www.ncrr.nih.gov/.
Information on Reengineering the Clinical Research En-
terprise can be obtained from http://nihroadmap.nih.
gov/clinicalresearch/overview-translational.asp.
No potential conﬂicts of interest relevant to this article
were reported.
The authors acknowledge the contributions of col-
leagues Dr. Rita Basu at the Mayo Clinic, Rochester,
Minnesota, and Dr. Gianna Toffolo and Dr. Claudio Cobelli
at the University of Padua, Padua, Italy.
REFERENCES
1. Bock G, Dalla Man C, Campioni M, Chittilapilly E, Basu R, Toffolo G,
Cobelli C, Rizza R. Pathogenesis of pre-diabetes: mechanisms of fasting
and postprandial hyperglycemia in people with impaired fasting glucose
and/or impaired glucose tolerance. Diabetes 2006;55:3536–3549
M
e
a
l
 
R
a
t
e
 
o
f
 
A
p
p
e
a
r
a
n
c
e
(
μ
m
o
l
/
(
k
g
•
m
i
n
)
)
100
80
60
40
20
0
pV=130
pV=160
pV=220
D
0
4
8
12
16
20
E
n
d
o
g
e
n
o
u
s
 
G
l
u
c
o
s
e
 
P
r
o
d
u
c
t
i
o
n
(
μ
m
o
l
/
(
k
g
•
m
i
n
)
)
E
0
-60 0 60 120 180
Time (min)
240 300 360 420
90
72
54
36
18
G
l
u
c
o
s
e
 
D
i
s
a
p
p
e
a
r
a
n
c
e
(
μ
m
o
l
/
(
k
g
•
m
i
n
)
)
F
0
-60 0 60 120 180
Time (min)
240 300 360 420
80
60
40
20
G
l
u
c
o
s
e
 
D
i
s
a
p
p
e
a
r
a
n
c
e
(
μ
m
o
l
/
(
k
g
•
m
i
n
)
)
C
0
3
6
9
12
15
18
E
n
d
o
g
e
n
o
u
s
 
G
l
u
c
o
s
e
 
P
r
o
d
u
c
t
i
o
n
(
μ
m
o
l
/
(
k
g
•
m
i
n
)
)
B
pV=130
pV=160
pV=220
0
20
40
60
80
100
M
e
a
l
 
R
a
t
e
 
o
f
 
A
p
p
e
a
r
a
n
c
e
(
μ
m
o
l
/
(
k
g
•
m
i
n
)
)
A
FIG. 4. Calculation of the systemic appearance of meal-derived glucose (A), EGP (B), and glucose disappearance (C) using the triple-tracer
technique and a one-compartment model. Note that changing the estimates of the pool fraction (pV) has little effect on calculated rates. In
contrast, using a dual-tracer approach, changing estimates of pV have marked effects on meal appearance (D), EGP (E), and glucose
disappearance (F). Modiﬁed and reprinted with permission from Basu et al. Am J Physiol Endocrinol Metab 2003;284:E55–E69.
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